BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:SMi's 21st Pain Therapeutics Conference will focus on looking 
 into research within pain therapeutics. In particular\, the long-term (HE
 AL) initiative will be discussed and its role in advancing research to re
 duce the risks of opioid use and misuse and improve pain management\, the
 reby reducing reliance on opioids and the national opioid public health c
 risis. Talks will also address the importance of sex\, gender and race in
  pain research\, including biomarkers\, molecular targets\, clinical and 
 experimental models of pain.\n\nThe conference also address cutting edge 
 drug discovery science\, preclinical development trends\, analysis of key
  clinical-stage pain therapies\, with a focus on highlighting the importa
 nce of biomarker discovery and its contribution to early stage studies on
  pain. This will be topped off with a panel debate on rethinking pain cli
 nical trials during the COVID-19 pandemic. And further look into treating
  painful osteoarthritis of the knee with a novel anti NGF\, anti-TNFα bis
 pecific fusion protein as well as therapeutic novelties signifying a para
 digm shift in migraine prevention. Additionally\, the conference will exp
 lore Botulinum neurotoxin\, Sigma 1 proteins and AP-325 as novel treatmen
 t for neuropathic pain as well as the high unmet medical need to develop 
 a novel non-drowsy skeletal muscle relaxant and explore pain genetics in 
 rare diseases as well as the Opioid Crisis and the future of addiction an
 d Pain Therapeutics.\n\nJoin Europe's leading Pain Therapeutics Virtual C
 onference in May 2021 to explore cutting edge drug discovery science and 
 key clinical-stage pain therapies in the pipeline\, bringing together lea
 ding pharmaceutical companies and to discuss solutions for the challenges
  of clinical trial design and conduct.#SMiPain\n\nKey Reasons to Attend t
 he Conference:- Discover which innovative new therapies are driving clini
 cal development including case studies from Novaramed and Vapogenix- Exam
 ine the best strategies to generate more funding in pain research clinica
 l trials to eliminate the issue of underfunding- Explore how COVID-19 has
  changed the experience of clinical trials and presented an opportunity t
 o reform the way we approach data verification\, data analysis and data c
 ollection- Understand the role of biomarkers in evaluating target engagem
 ent of new drugs and predicting analgesic efficacy- Virtual Conference Be
 nefits include virtual exhibition booths packed with information\, networ
 king features to chat and share contact details with other attendees\, an
 d virtual meetings and networking socials.\n
DTEND:20210511T170000
DTSTAMP:20260512T214933Z
DTSTART:20210510T083000
LOCATION:Online\, \,
SEQUENCE:0
SUMMARY:SMi's 21st Pain Therapeutics Conference will focus on looking into
  research within pain therapeutics. In particular\, the long-term (HEAL) 
 initiativ...
UID:744a5cc6-1139-4fa5-940f-5395c0b91fb4
END:VEVENT
END:VCALENDAR